English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The purpose of this study is to compare the sensitivity of  68 Ga-DOTA-JR11 and  68 Ga-DOTA-TATE PET/CT for detecting the responsible tumor of tumor-induced osteomalacia (TIO) and investigate if  68 Ga-DOTA-JR11 PET/CT can identify the culprit tumor of TIO in multiple suspicious lesions in  68 Ga-DOTA-TATE PET/CT.    Methods  A total of 19 patients with suspected TIO were prospectively recruited in this study. Each patient underwent whole-body PET/CT scan 40–60 min postinjection using  68 Ga-DOTA-TATE and  68 Ga-DOTA-JR11 on the same PET/CT, respectively in sequence, and on consecutive days. The diagnosis of TIO was confirmed by the combination of the postsurgical pathological results of the tumor and clinical information.    Results  Among the 19 patients with TIO who were included in this study, culprit tumors from all patients were confirmed pathologically.  68 Ga-DOTA-TATE PET/CT positively identified the causative tumor in 18/19 patients, whereas  68 Ga-DOTA-JR11 PET/CT was positive in 11/19 patients (94.7% vs. 57.9%, respectively;  p  &amp;lt; 0.05).  68 Ga-DOTA-TATE PET/CT demonstrated more than one increased focal activity in 7 patients for a total of 16 lesions (3 lesions each in 2 patients and 2 lesions each in the rest 5 patients). However, seven of these 16 lesions showed concordant results on  68 Ga-DOTA-JR11 PET/CT by demonstrating increased activity (one lesion in each of the 7 patients). The surgical specimens of the lesions in these 7 patients confirmed the phosphaturic mesenchymal tumor. A total of 11 culprit tumors were positive in both  68 Ga-DOTA-TATE and  68 Ga-DOTA-JR11 PET/CT. The SUVmax of 11 culprit tumors was significantly higher on  68 Ga-DOTA-TATE PET/CT compared with that on  68 Ga-DOTA-JR11 PET/CT (17.8 ± 12.5 vs. 6.8 ± 6.2;  p  &amp;lt; 0.05).    Conclusions   68 Ga-DOTA-TATE PET/CT is more sensitive to  68 Ga-DOTA-JR11 PET/CT in the detection of the culprit tumor of TIO. However,  68 Ga-DOTA-JR11 PET/CT might be helpful to identify the tumor in multiple suspicious lesions in  68 Ga-DOTA-TATE PET/CT.    Clinical Trial Registration   clinicaltrials.gov , identifier NCT 04689893.

Head-to-Head Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study